thrombocytopenic purpura
thrombocytopenic purpura
Explore linked clinical trials. Standard reference: MONDO:0043768152 results · Page 1 of 7
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) | Cytopenia, Evans syndrome, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-10-09 | NCT07421167 | |
| A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT06721013 | |
| A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, blood coagulation disease, blood platelet disease, hematologic disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombophilia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura | Recruiting | Not stated | 2026-10-02 | NCT07353099 | |
| A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Not stated | 2026-10-01 | NCT07786077 | |
| Comparative Autoantibody and Immunologic Cell Marker Study | AIDS, Blood-Borne Infections, Chronic Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cytopenia, DNA Virus Infections, Digestive System Diseases, Disease Attributes, Epstein-Barr virus infection, Flaviviridae infectious disease, Genital Diseases, Guillain-Barre syndrome, HIV infectious disease, Hemic and Lymphatic Diseases, Hemorrhage, Herpesviridae infectious disease, Immunoglobulin G4-Related Disease, Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Post-Infectious Disorders, Purpura, Thrombocytopenic, Idiopathic, RNA Virus Infections, Sepsis, Signs and Symptoms, Sjogren syndrome, Skin Manifestations, Skin and Connective Tissue Diseases, Slow Virus Diseases, Stomatognathic Diseases, Systemic Inflammatory Response Syndrome, Tumor Virus Infections, Undifferentiated Connective Tissue Diseases, Urogenital Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, autoimmune disorder of the nervous system, autoimmune lymphoproliferative syndrome, blood coagulation disease, blood platelet disease, connective tissue disorder, demyelinating disease, diffuse scleroderma, dry eye syndrome, eye disorder, graft versus host disease, hematologic disorder, hemorrhagic disease, hepatitis, hepatitis C virus infection, hereditary disease, immune system disorder, immunoproliferative disorder, inborn error of immunity, infectious disease, juvenile idiopathic arthritis, lacrimal apparatus disorder, lentivirus infection, liver disorder, lymphatic system disorder, lymphoproliferative syndrome, mouth disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, polyradiculoneuropathy, purpura, rheumatic disorder, rheumatoid arthritis, salivary gland disorder, sexually transmitted disease, skin disorder, systemic lupus erythematosus, systemic sclerosis, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy, uterine carcinosarcoma, viral hepatitis, viral infectious disease, viral sexually transmitted disease | Enrolling by invitation | Not stated | 2026-10-01 | NCT02422875 | |
| TGD001 Treatment in Thrombotic Microangiopathies | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT07459114 | |
| A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, autoimmune thrombocytopenic purpura, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 / Phase 3 | 2026-09-24 | NCT07194850 | |
| A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Active, not recruiting | Phase 2 | 2026-09-24 | NCT05885555 | |
| Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias | Cytopenia, Disease Attributes, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Recurrence, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Not yet recruiting | Phase 1 | 2026-09-23 | NCT07765966 | |
| A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Active, not recruiting | Phase 3 | 2026-09-23 | NCT04812925 | |
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, autoimmune hemolytic anemia, warm type, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 1 / Phase 2 | 2026-09-22 | NCT07549698 | |
| A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 3 | 2026-09-18 | NCT06722235 | |
| A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 3 | 2026-09-17 | NCT07700238 | |
| Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-09-14 | NCT07104565 | |
| Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-09-14 | NCT07095127 | |
| A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 3 | 2026-09-11 | NCT07059000 | |
| Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Not yet recruiting | Not applicable | 2026-09-10 | NCT07811622 | |
| SG301-SC Injection Safety Study in Subjects With Primary ITP Patients | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 2 | 2026-09-09 | NCT07710248 | |
| A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 3 | 2026-09-09 | NCT06948318 | |
| Selective Mediterranean Diet in Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Not yet recruiting | Not applicable | 2026-09-03 | NCT07798050 | |
| OM336 in Autoimmune Cytopenias | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, anemia, autoimmune disease, autoimmune hemolytic anemia, blood coagulation disease, blood platelet disease, hematologic disorder, hemolytic anemia, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 1 | 2026-09-03 | NCT07083960 | |
| Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, blood coagulation disease, blood platelet disease, connective tissue disorder, hematologic disorder, hemorrhagic disease, immune system disorder, musculoskeletal system disorder, purpura, rheumatic disorder, rheumatoid arthritis, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Active, not recruiting | Phase 1 | 2026-09-01 | NCT07675226 | |
| A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, blood coagulation disease, blood platelet disease, hematologic disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombophilia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura | Not yet recruiting | Not stated | 2026-08-28 | NCT07429942 | |
| Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 4 | 2026-08-26 | NCT07788456 | |
| A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Active, not recruiting | Phase 3 | 2026-08-21 | NCT05653219 |